|
68 Companies |
|
79 Products |
|
79 Products |
|
71 Mechanisms of Action |
|
0 Trials |
|
484 News |
|
| «12345678910» |
- Clinical: A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis (clinicaltrials.gov) - Aug 27, 2012
P=N/A, N=100, Recruiting, Sponsor: Yale University
- | SB-705498 / GSK
New P1 trial: Investigation of Topical SB705498 on Healthy Volunteers (clinicaltrials.gov) - Aug 26, 2012
P1, N=16, Completed, Sponsor: GlaxoSmithKline
- ||| BMS-981164 / BMS
Enrollment open: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (clinicaltrials.gov) - Aug 22, 2012
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting
- Trial completion, IO biomarker: KIR: Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma (clinicaltrials.gov) - Aug 20, 2012
P=N/A, N=495, Completed, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| montelukast / Generic mfg.
Trial completion: The Effectiveness of Montelukast on Atopic Dermatitis in Koreans (clinicaltrials.gov) - Aug 14, 2012
P=N/A, N=54, Completed, Sponsor: Pyun BokYang
Recruiting --> Completed Not yet recruiting --> Completed
- Enrollment change: Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=31, Completed, Sponsor: Wake Forest School of Medicine
Not yet recruiting --> Completed N=15 --> 31
- Enrollment change: Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=45, Completed, Sponsor: Wake Forest School of Medicine
N=15 --> 31 N=30 --> 45
- Trial completion: Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=31, Completed, Sponsor: Wake Forest School of Medicine
N=30 --> 45 Recruiting --> Completed
- Trial completion: Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=45, Completed, Sponsor: Wake Forest School of Medicine
Recruiting --> Completed Active, not recruiting --> Completed
- Clinical: Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management (clinicaltrials.gov) - Aug 6, 2012
P=N/A, N=37, Completed, Sponsor: Dermatology & Aesthetics of Wicker Park
- | Eucrisa (crisaborole) / Pfizer
New P1/2 trial: Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis (clinicaltrials.gov) - Jul 26, 2012
P1/2, N=23, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
- |||| mapracorat (BOL-303242-X) / Bayer
Trial completion: Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD) (clinicaltrials.gov) - Jul 22, 2012
P2, N=197, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| mapracorat (BOL-303242-X) / Bayer
Trial completion: Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD) (clinicaltrials.gov) - Jul 18, 2012
P2, N=263, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | mapracorat (BOL-303242-X) / Bayer
Enrollment change: HPA Axis Study in Japanese Adults (clinicaltrials.gov) - Jul 18, 2012
P2, N=12, Completed, Sponsor: Bayer
Active, not recruiting --> Completed N=10 --> 12
- | mapracorat (BOL-303242-X) / Bayer
Trial completion: HPA Axis Study in Japanese Adults (clinicaltrials.gov) - Jul 18, 2012
P2, N=12, Completed, Sponsor: Bayer
N=10 --> 12 Active, not recruiting --> Completed
- | Dupixent (dupilumab) / Sanofi, Regeneron
New P2 trial: Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) (clinicaltrials.gov) - Jul 10, 2012
P2, N=31, Completed, Sponsor: Regeneron Pharmaceuticals
- Clinical: Effectiveness of Melatonin for Sleep Disturbances in Children With Atopic Dermatitis (clinicaltrials.gov) - Jul 9, 2012
P=N/A, N=40, Recruiting, Sponsor: National Taiwan University Hospital
- Trial completion, HEOR, Cost effectiveness: OnderHUIDs: Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - Jul 3, 2012
P4, N=50, Completed, Sponsor: University Hospital, Ghent
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change: Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis (clinicaltrials.gov) - Jun 27, 2012
P2, N=13, Completed, Sponsor: University of Medicine and Dentistry New Jersey
Active, not recruiting --> Completed N=40 --> 13
- Enrollment change: Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis (clinicaltrials.gov) - Jun 17, 2012
P2, N=183, Completed, Sponsor: University of California, Davis
N=40 --> 13 N=140 --> 183
- Trial completion: Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis (clinicaltrials.gov) - Jun 17, 2012
P2, N=183, Completed, Sponsor: University of California, Davis
N=140 --> 183 Not yet recruiting --> Completed
- ||| BMS-981164 / BMS
New P1 trial: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (clinicaltrials.gov) - Jun 6, 2012
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
- | Trial completion: Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults (clinicaltrials.gov) - May 28, 2012
P2, N=17, Completed, Sponsor: Oculus Innovative Sciences, Inc.
Not yet recruiting --> Completed Recruiting --> Completed
- REGN846 / Regeneron
New P1/2 trial: Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis (clinicaltrials.gov) - May 23, 2012
P1/2, N=19, Terminated, Sponsor: Regeneron Pharmaceuticals
- ||||| Eucrisa (crisaborole) / Pfizer
New P2 trial: Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis (clinicaltrials.gov) - May 17, 2012
P2, N=86, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
- | JNJ-39758979 / J&J
Trial termination: A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis (clinicaltrials.gov) - May 15, 2012
P2, N=88, Terminated, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Completed Recruiting --> Terminated; This study was terminated prematurely due to 2 cases of agranulocytosis.
- |||| tacrolimus topical / Generic mfg.
Trial completion: Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis (clinicaltrials.gov) - May 14, 2012
P2, N=159, Completed, Sponsor: BioCis Pharma Ltd
Recruiting --> Terminated; This study was terminated prematurely due to 2 cases of agranulocytosis. Active, not recruiting --> Completed
- | New P2 trial, IO biomarker: 2ndDermisII: Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis (clinicaltrials.gov) - May 10, 2012
P2, N=100, Active, not recruiting, Sponsor: Universidade do Porto
- New P3 trial: Vitamin D Supplementation in Polymorphic Light Eruption (clinicaltrials.gov) - May 8, 2012
P3, N=36, Recruiting, Sponsor: Medical University of Graz
- Zoryve (roflumilast cream) / Arcutis
Enrollment change: A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM) (clinicaltrials.gov) - May 3, 2012
P2, N=0, Withdrawn, Sponsor: Nycomed
Active, not recruiting --> Completed N=40 --> 0
- | tacrolimus topical / Generic mfg.
New P4 trial: Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis (clinicaltrials.gov) - May 1, 2012
P4, N=104, Completed, Sponsor: Pusan National University Hospital
- Enrollment open: Vulvar Contact Dermatitis Resulting From Urine Incontinence (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=400, Recruiting, Sponsor: Meir Medical Center
N=40 --> 0 Not yet recruiting --> Recruiting
- Enrollment open: Inhibitory Receptors in Eosinophils of Atopic Subjects (clinicaltrials.gov) - Apr 22, 2012
P=N/A, N=40, Recruiting, Sponsor: Meir Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Trial completion: 0405-01-04: Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis (clinicaltrials.gov) - Apr 8, 2012
P2, N=114, Completed, Sponsor: Fougera Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| New P2 trial: Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis (clinicaltrials.gov) - Apr 5, 2012
P2, N=64, Recruiting, Sponsor: Tecno Sun SRL
- Enrollment change: Effect of Pollen Challenges on Dermal Symptoms in Patients With Atopic Dermatitis (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=18, Completed, Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine
Recruiting --> Completed N=38 --> 18
- Trial completion: Effect of Pollen Challenges on Dermal Symptoms in Patients With Atopic Dermatitis (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=18, Completed, Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine
N=38 --> 18 Enrolling by invitation --> Completed
- | Altabax (retapamulin) / GSK, Almirall
Enrollment change: Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis (clinicaltrials.gov) - Mar 29, 2012
P4, N=29, Completed, Sponsor: Derm Research, PLLC
Enrolling by invitation --> Completed N=40 --> 29
- Clinical: Narrowband UVB for Children With Moderate to Severe Atopic Eczema (clinicaltrials.gov) - Mar 29, 2012
P=N/A, N=58, Completed, Sponsor: Royal Victoria Infirmary
- |||||||||| Eumovate (clobetasone butyrate) / GSK
New P3 trial: Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety (clinicaltrials.gov) - Mar 29, 2012
P3, N=240, Completed, Sponsor: GlaxoSmithKline
- ||||| cobamamide liposomal (HL009) / Daewoong Pharma
New P2 trial: Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Mar 29, 2012
P2, N=120, Completed, Sponsor: HanAll BioPharma Co., Ltd.
- | Altabax (retapamulin) / GSK, Almirall
Trial completion: Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis (clinicaltrials.gov) - Mar 29, 2012
P4, N=29, Completed, Sponsor: Derm Research, PLLC
N=40 --> 29 Recruiting --> Completed
- ||| MRX 6 / Akari Therap
Trial initiation date: Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis (clinicaltrials.gov) - Mar 24, 2012
P1/2, N=80, Recruiting, Sponsor: Hadassah Medical Organization
Recruiting --> Completed Initiation date: May 2009 --> Mar 2011
- ||| Trial initiation date: Determination of Safety and Consumers' Satisfaction of Moussik Versus Desitin Creamy Ointment in Diaper Rash Prophylaxis (clinicaltrials.gov) - Mar 19, 2012
P4, N=60, Not yet recruiting, Sponsor: Trima, Israel Pharmaceutical Products
Initiation date: May 2009 --> Mar 2011 Initiation date: Oct 2011 --> Jan 2013
- | ligelizumab (QGE 031) / Novartis
New P2 trial: A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients (clinicaltrials.gov) - Mar 11, 2012
P2, N=22, Completed, Sponsor: Novartis Pharmaceuticals
- |||| Trial completion, Metastases: Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application (clinicaltrials.gov) - Mar 8, 2012
P4, N=74, Completed, Sponsor: Galderma Brasil Ltda.
Initiation date: Oct 2011 --> Jan 2013 Recruiting --> Completed
- ||||| Dupixent (dupilumab) / Sanofi, Regeneron
New P2 trial: Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Mar 6, 2012
P2, N=109, Completed, Sponsor: Regeneron Pharmaceuticals
- ||| MEDI 4212 / AstraZeneca
New P1 trial: A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL (clinicaltrials.gov) - Mar 1, 2012
P1, N=86, Completed, Sponsor: MedImmune LLC
- ||| Enrollment change: Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants (clinicaltrials.gov) - Feb 29, 2012
P4, N=200, Completed, Sponsor: Stiefel, a GSK Company
Recruiting --> Completed N=132 --> 200
- |||||||||| betamethasone/dexchlorpheniramine maleate / Generic mfg., prednisolone / Generic mfg.
New P3 trial: Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment (clinicaltrials.gov) - Feb 6, 2012
P3, N=140, Not yet recruiting, Sponsor: EMS